Barinthus Biotherapeutics plc (BRNS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) has a cash flow conversion efficiency ratio of -0.127x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.73 Million) by net assets ($84.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BRNS stock market capitalisation for the company's overall valuation and market capitalisation.
Barinthus Biotherapeutics plc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Barinthus Biotherapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Barinthus Biotherapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Barinthus Biotherapeutics plc ranked by their cash flow conversion efficiency. Explore BRNS operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lotus KFM Bhd
KLSE:8303
|
0.005x |
|
KNW Co. Ltd
KQ:105330
|
0.026x |
|
ENERGIA IN.Y DES. EO 025
F:F63
|
N/A |
|
Sinaran Advance Group Bhd
KLSE:5172
|
0.136x |
|
DL Holdings Co Ltd Preferred
KO:000215
|
0.035x |
|
Hanwha Chemical Corp Pref
KO:009835
|
-0.030x |
|
Abko Co. Ltd
KQ:129890
|
-0.134x |
|
Parkson Retail Group Limited
F:P5IB
|
0.104x |
Annual Cash Flow Conversion Efficiency for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Barinthus Biotherapeutics plc from 2019 to 2024. View Barinthus Biotherapeutics plc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $130.13 Million | $-28.94 Million | -0.222x | +18.34% |
| 2023-12-31 | $187.00 Million | $-50.92 Million | -0.272x | -358.95% |
| 2022-12-31 | $243.20 Million | $-14.43 Million | -0.059x | +54.01% |
| 2021-12-31 | $252.56 Million | $-32.58 Million | -0.129x | -103.68% |
| 2020-12-31 | $-3.15 Million | $-11.03 Million | 3.504x | +312.44% |
| 2019-12-31 | $-22.08 Million | $-18.76 Million | 0.850x | -- |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more